Kyle W. Gano
Net Worth
Last updated:
What is Kyle W. Gano net worth?
The estimated net worth of Mr. Kyle W. Gano is at least $43,045,890 as of 13 Feb 2024. He owns shares worth $17,951,396 as insider, has earned $16,553,854 from insider trading and has received compensation worth at least $8,540,640 in Neurocrine Biosciences, Inc..
What is the salary of Kyle W. Gano?
Mr. Kyle W. Gano salary is $711,720 per year as Chief Bus. Devel. and Strategy Officer in Neurocrine Biosciences, Inc..
How old is Kyle W. Gano?
Mr. Kyle W. Gano is 52 years old, born in 1973.
What stocks does Kyle W. Gano currently own?
As insider, Mr. Kyle W. Gano owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Neurocrine Biosciences, Inc. (NBIX) | Chief Bus. Devel. and Strategy Officer | 135,166 | $132.81 | $17,951,396 |
What does Neurocrine Biosciences, Inc. do?
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Kyle W. Gano insider trading
Neurocrine Biosciences, Inc.
Mr. Kyle W. Gano has made 53 insider trades between 2013-2024, according to the Form 4 filled with the SEC. Most recently he sold 1,352 units of NBIX stock worth $179,674 on 13 Feb 2024.
The largest trade he's ever made was exercising 75,000 units of NBIX stock on 2 Jan 2024. As of 13 Feb 2024 he still owns at least 135,166 units of NBIX stock.
Neurocrine Biosciences key executives
Neurocrine Biosciences, Inc. executives and other stock owners filed with the SEC:
- Dr. Eiry Wyn Roberts (61) Chief Medical Officer
- Dr. Kevin C. Gorman Ph.D. (67) Chief Executive Officer & Director
- Mr. Eric S. Benevich (60) Chief Commercial Officer
- Mr. Kyle W. Gano (52) Chief Bus. Devel. and Strategy Officer
- Mr. Matthew C. Abernethy (45) Chief Financial Officer